Alpha Cognition Inc. (OTC:ACOGF – Get Free Report) shares fell 1.3% during mid-day trading on Thursday . The stock traded as low as C$0.52 and last traded at C$0.52. 33,504 shares were traded during mid-day trading, a decline of 31% from the average session volume of 48,582 shares. The stock had previously closed at C$0.53.
Alpha Cognition Trading Down 1.3 %
The stock has a market capitalization of C$61.82 million, a PE ratio of -3.74 and a beta of 2.87. The firm’s fifty day moving average is C$0.54 and its 200-day moving average is C$0.56.
Alpha Cognition Company Profile
Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
See Also
- Five stocks we like better than Alpha Cognition
- What Does Downgrade Mean in Investing?
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Top Stocks Investing in 5G Technology
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
